08.25.20 to 08.27.20
New Delhi, India

This spring and summer, the Sabin Vaccine Institute (Sabin) has been amplifying the voices of parents who immunize through the Give Your Kids A Shot campaign on Twitter

Sabin Vaccine Institute Receives $20.5 Million from BARDA with Potential of up to $128 Million to Develop Ebola Sudan and Marburg Vaccines

WASHINGTON, D.C. – The Sabin Vaccine Institute (Sabin) today announced a funding award of $20.5 million with options for an additional $107.5 million from the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services.
The success of immunization programs relies heavily on immunization program managers, who facilitate every aspect of immunization programs, from cost-effective procurement of vaccines to the vigilant monitoring of vaccine safety and efficacy. Sabin’s IAIM Network is the largest international network of immunization managers, offering opportunities to connect, share knowledge and strengthen skills required to effectively implement immunization programs.

Vaccines save millions of lives every year, but recent outbreaks demonstrate the tenuous nature of this achievement. The Sabin Vaccine Institute (Sabin) is launching a research program to better understand the factors leading some to accept vaccination and others to delay or refuse it.

The success of immunization programs relies heavily on immunization program managers, who facilitate every aspect of immunization programs, from cost-effective procurement of vaccines to the vigilant monitoring of vaccine safety and efficacy. Sabin’s IAIM Network is the largest international network of immunization managers, offering opportunities to connect, share knowledge and strengthen skills required to effectively implement immunization programs.

Sabin Vaccine Institute Elects New Trustees Bringing Expertise to Support Program Growth

WASHINGTON, D.C. – The Sabin Vaccine Institute (Sabin) announces the appointment of three new members to its Board of Trustees. Joining the Board are Drs. Elizabeth Fox, Saad Omer and Jacqueline Shea, well-respected leaders whose range of skills and experience promise to advance Sabin’s aim to ensure all people, everywhere get the vaccines they need.

GSK Grants Exclusive Technology License For Clinical-Stage Ebola Vaccines To Sabin Vaccine Institute

LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) today announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus.

Pages